What are the side effects of Thymosin Alpha-1?

Users most often report flushing, rapid hr, nausea, unwell feeling, local irritation. Side effects came up 7 times across 71 reports.

Thymosin Alpha-1 side effects

Q: Is Thymosin Alpha-1 safe?

Thymosin Alpha-1 is not an approved supplement and carries serious risks. User reports can't establish safety. PubMed lists 11 meta-analyses and 35 randomized trials. Talk to a doctor or pharmacist, especially if you take other medication.

Across 71 first-hand reports, people mentioned a side effect 7 times (about 10 per 100 reports). The most common: flushing, rapid hr, nausea. User reports show what people notice — they can't tell you whether Thymosin Alpha-1 is safe for you.

High-risk compound. Not an approved supplement; serious and sometimes irreversible risks, banned in sport, may be restricted where you live.

Reported side effects

flushing1

rapid hr1

nausea1

unwell feeling1

local irritation1

redness1

histamine reaction1

In their own words

“later I noticed it with immune modulating compounds like Thymosin alpha 1”

Didn't helpRead the discussion ↗

“I used it personally (along with patients) from March until being vaccinated in December last year. Zero side effects and zero infections in all subjects.”

HelpedRead the discussion ↗

“I would say that TA1, if anything, was positive... I think I may have been better joint pain wise when on the TA1”

HelpedRead the discussion ↗

“The others Ive tried I would not repurchase- mots-c, nad+, semax, selank, and thymosin alpha 1.”

Didn't helpRead the discussion ↗

“Most frequently, I see the peptide Thymosin Alpha-1 recommended. TA1 is a peptide that increases TCell (your killer cells) production in mammals.”

MixedRead the discussion ↗

“I took thymosin alpha 1 the other day and it made my throat slightly swell and I was sneezing like crazy.”

Didn't helpRead the discussion ↗

Is Thymosin Alpha-1 safe? What the research covers

AResearch: Strong11 meta-analyses · 35 randomized trials on PubMed

BMC Gastroenterol · 2020

The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis

Conclusion: ETV plus Tα1 might lead to a higher clinical response and a lower comprehensive adverse reaction rate in HBV-related patients with cirrhosis, compared to ETV alone. However, the whole patients included in this meta-analysis were from Chinese mainland, so that more worldwide RCTs with a larger sample size are needed to verify the current findings.